Geriatric Grand Rounds. Managing Behavioural and Psychological Symptoms of Dementia (BPSD) in Patients with Alzheimer s Disease
|
|
- Randall Robertson
- 6 years ago
- Views:
Transcription
1 Geriatric Grand Rounds Visit web sites: Tuesday, April 14, :00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this event have been asked to disclose to the audience any involvement with industry or other organizations that may potentially influence the presentation of the educational material. Disclosure will be done both verbally and using a slide or handout. for handouts, poster, schedule, subscription: for on-demand archive of previous presentations: Managing Behavioural and Psychological Symptoms of Dementia (BPSD) in Patients with Alzheimer s Disease Medical Director, Geriatric Psychiatry and Associate Professor University of Manitoba Geriatric Psychiatrist, St. Boniface Hospital, Winnipeg, Manitoba Conflicts Today s Learning Objectives Id vs Superego Funding for this talk from Lundbeck Also have received funding within the past year from Pfizer, Novartis, Janssen and Wyeth for presentations No ongoing research funding from Pharma Following this presentation, participants will : Recognize the spectrum of BPSD and it s complexity Understand the role of psychotropic medication within a comprehensive best practice approach to BPSD Be aware of some pragmatic tools to support care strategies Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 1 of 20
2 BPSD Symptom Clusters BPSD Symptom Clusters Apathy Aggression Physical aggression Verbal aggression Aggressive resistance to care Pacing Repetitive actions Dressing/undressing Restless/anxious Agitation Apathy Aggression Physical aggression Verbal aggression Aggressive resistance to care Pacing Repetitive actions Dressing/undressing Restless/anxious Agitation Withdrawn Lacks interest Amotivation Sad Tearful Hopeless Irritable/screaming Guilty Anxious Suicidal Euphoria Pressured speech Irritable Mania Hallucinations Delusions Misidentification Suspicious Psychosis Withdrawn Lacks interest Amotivation Sad Tearful Hopeless Irritable/screaming Guilty Anxious Suicidal Euphoria Pressured speech Irritable Mania Hallucinations Delusions Misidentification Suspicious Psychosis Depression Depression Group Discussion Questions Prevalence of BPSD What BPSDs do you most commonly see in your practice? What are the consequences of BPSD? Estimated to affect 63% of community-dwelling patients with dementia 1,2,3 Symptoms are increasingly prevalent and disturbing in severe AD 4 In particular, agitation and aggressive behaviours affect roughly 2/3 of patients with severe AD 4 Also common in severe AD: depression, apathy, anxiety, delusions, and hallucinations 4 1. Cohen-Mansfield et al. Int Psychogeriatr 1995;7: Hogan DB et al. Alzheimers Dement 2007;3: Jost BC. J Am Geriatr Soc 1996;44(9): Herrmann N et al. Alzheimers Dement 2007;3: Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 2 of 20
3 Meet Henry: A 74-Year-Old Recently Admitted to Long-Term Care (LTC) Case Study: Henry Admitted to nursing home 6 weeks ago 3 weeks prior to admission, Henry s wife (and attentive caregiver) passed away Henry has a 4-yr history of Alzheimer s disease (AD) 2-yr history of donepezil 10 mg OD, no other AD meds Current MMSE = 20/30 Requires assistance for dressing and hygiene 6 feet tall, 180 pounds, no mobility problems Henry: Medical History and Other Current Medications This Morning... Long-term history of high BP Taking HCTZ 25 mg qd and enalapril 5 mg qd Chronic lower back pain Taking Tylenol #2 as needed and Naproxyn 500 mg TID Esophageal reflux Taking Ranitidine 75 mg BID and Diphenhydramine 50 mg after evening meal Previous cataract surgery A fight breaks out at Henry s breakfast table The cause of the fight is unclear Henry assaults another resident, who falls to the ground and breaks his arm Henry is screaming; everyone is upset Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 3 of 20
4 Group Discussion Question With Any New-Onset Behavioural Issue... Henry is immediately started on an antipsychotic. What do you think of this treatment approach? Delirium Psychological Issues Side Effect of Medication RULE OUT Depression Physical Triggers Environmental Triggers Possible Causes of Delirium The Big 3 1. DRUGS* Any new drug (beware additive anticholinergics) 2. Infection 3. Metabolic The Little 3 1. Pain 2. Urinary retention/infection 3. Fecal impaction/loading Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 4 of 20
5 Ruling Out Possible Causes for Henry s BPSD If you Choose an Antipsychotic Consider medical illness: Urinary tract infection or other infection Poorly controlled pain PRN s used causing confusion Start low and go slow, but be persistent Counsel substitute decision-maker about risks and alternatives and chart How could you start Henry on an antipsychotic? Check labs: Electrolytes Creatinine Glucose Hemoglobin Urinalysis Establish baseline frequency and severity, then risperidone 0.25mg BID for one week Review target symptom and any extrapyramidal symptoms If beneficial, continue with plan being to taper in the next few months If not beneficial, either discontinue or titrate up BPSDs are Associated with Poor Patient Outcomes... BPSDs are Associated with Poor Patient Outcomes... More rapid cognitive and functional decline 1 Chicken Use of antipsychotic medication 2,5 Increased physical frailty and mortality 1,5 Earlier placement in long-term care (up to 2 years earlier) 3,4 Or Egg Increased caregiver burden 5 1. Hermann N et al. Alzheimers Dement 2007;3: Margallo-Lana M et al. Int J Geriatr Psychiatry 2001;16(1): Phillips VL, Diwan S. J Am Geriatr Soc 2003;51: Hogan DB et al. Alzheimers Dement 2007;3: Herrmann N, Gauthier S. CMAJ 2008;179(12): Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 5 of 20
6 Cardiovascular Risks Associated with Antipsychotics In 2005: FDA issued black box warning about increased risk of MI and CVA Health Canada sent an advisory to HCPs In 2007: Prospective trial showed no risk of death In early 2009, risk of death found in: U.S. retrospective analysis (n=276,907) U.K. prospective study (n=165) with up to 42 months follow-up Raivio MM, et al. Am J Geriatr Psychiatry 2007;15(5): Ray WA, et al. N Engl J Med 2009;360: Ballard C, et al. Lancet Neurol 2009;8(2): Risk of Sudden Cardiac Death Higher with Antipsychotics: Retrospective Study Risk of Sudden Cardiac Death Higher with Antipsychotics: Retrospective Study New England Journal of Medicine, January 2009 Retrospective cohort study of U.S. Medicaid enrollees Pts taking typical (n=44,218) or atypical (n=46,089) antipsychotics, or matched controls (186,600) Adapted from Ray WA, et al. N Engl J Med 2009;360: Adjusted Incidence Rate Ratios Overall For Low Dose For High Dose p-value (low vs. high) Typical p<0.001 Atypical p=0.01 Incident Rate Ratio Low Dose Moderate Dose High Dose 3,5 p= p< ,5 2 1,5 1 0,5 0 Typical Antipsychotics Agent Atypical Antipsychotic Agent No. of Deaths No. of Person-Years 21,438 33,671 31,626 10,435 41,513 27,641 Incidence-Rate Ratio % CI Adapted from Ray WA, et al. N Engl J Med 2009;360: Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 6 of 20
7 Risk of Mortality Higher with Atypical Antipsychotics: Prospective Trial Risk of Mortality Higher with Atypical Antipsychotics: Prospective Trial The Lancet, e-pub January, 2009 U.K. randomized, placebo-controlled, parallel, two-group treatment discontinuation trial Continue antipsychotics for 12 months (n=83) vs. switch to placebo (n=82) + long-term follow-up Probability of Survival 12-month 24-month 36-month 42-month Antipsychotic 70% 46% 30% 26% Placebo 77% 71% 59% 52% Overall hazard ratio = 0.58; p=0.03 Kaplan-Meier Survival Estimate Cumulative survival (%) Number at risk (deaths) Continue treatment Placebo Placebo Continue treatment HR 0.58 (95% CI 0.35 to 0.95); Log-rank p= (19) 64 (15) 45 (13) 49 (3) 20 (6) 29 (6) 9 (1) 19 (2) 4 (0) 8 (1) Adapted from Ballard C, et al. Lancet Neurol 2009;8(2): Adapted from Ballard C, et al. Lancet Neurol 2009;8(2): Antipsychotics and stroke risk Madness of modern medicine Douglas and Smeeth s study of the risk of stroke with antipsychotic drugs highlights modern medicine s flawed perspective.1 Medicine once served to make patients better, alleviating symptoms and healing disease. Now it seems to have degenerated into a risk reducing, patient stratifying, life years adding bioscience disregarding the individual patient s needs. To deny a patient good treatment for disturbing and harassing complaints because of worries about possible side effects is unethical. Nobody would question prescribing morphine for terminal analgesia. Patients at the end of their life with dementia related behavioural problems should be able to expect proper treatment. To withhold this treatment for spurious and debatable reasons is "madicine." Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 7 of 20
8 Risperidone and Olanzapine similar Placebo worst Norwegian Nursing Home Study: Symptoms Persisted Despite Psych Treatment Risperidone and Quetiapine similar Olanzapine worst 1-year study of 1,163 nursing home patients (80% had dementia) 84% were symptomatic at some point during the year Most patients (75 to 88%) who were taking antidepressants, antipsychotics or psychotropics at baseline continued taking these throughout the year Despite psychiatric medication, baseline symptoms generally persisted over the year Selbaek G et al. Am J Geriatr Psychiatry 2008;16(7): Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 8 of 20
9 60 How Likely are meds to be stopped? Prev Persist Incidence % of patients on med n at start and end of study Antidepressants 79% Antipsychotics 75% Any Psychotropic 88% 10 0 Irritability Apathy Aggression Delusions Depression DART Randomized discontinuation of antipsychotics in patient with dementia Setting UK nursing or residential homes Randomized to standard dosing 12 month duration Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 9 of 20
10 SO. IF they increase risk of stroke, they increase risk of death, they increase risk of falls AND they have limited efficacy. WHY Are they used so often? P.I.E.C.E.S. Framework to Understand and Address BPSD Complexity P hysical problem or discomfort I ntellectual/cognitive changes E motional C apabilities E nvironment S ocial/cultural Non-Pharmacological Interventions Environmental interventions 1 Validation therapy 2 Best friend approach 3 Simulated presence therapy 4 Pet therapy Activities, exercise, social interaction Behaviour modification (e.g., scheduled toileting) 1. Moak GS. The Clinical View: Geriatric psychiatry in long term care. 2004;2(2): Feil N, et al. The Validation Breakthrough Bell V, Troxel D. The Best Friend Approach to Alzheimer Care Woods P,Ashley J. Geriatr Nurs 1995;16(1):9-14. Cont d... Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 10 of 20
11 Effective Non-Pharmacological Interventions Bright light therapy Environmental white noise (e.g., soft background music or lullabies) Music therapy: may lessen some symptoms and improve QoL 1,2 Snoezelen multisensory interventions (involving fibreoptic lights and touch): can provide relief from acute or chronic pain by offering distraction 3 Stimulates passive pts, soothes agitated pts Aromatherapy (lemon balm or lavender oil) can sometimes be an alternative to neuroleptics 2 1. Raglio A, et al. Alz Dis Assoc Dis. 2008;22(2) Alzheimer s Society. Complementary and alternative medicine and Dementia. Available at: alzheimers.org.uk/factsheet/ Burns A, et al. BMJ 2002;325: Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 11 of 20
12 Skills required from Nursing Staff Simple Care? Post-Intervention Establish visual contact Approach the patient slowly, head-on If you fear for your safety, place a chair between you Direct the patient calmly and firmly (e.g., Please look at me ) Gently touch the patient s hand (after asking permission) Recognize what the patient is feeling in order to make him/her feel understood (e.g., You are angry right now ) If needed, remove the patient to a calmer area If de-escalation is needed before you intervene, calmly divert the patient s attention (e.g., Henry, look out the window ) Phaneuf, M. Le vieillissement perturbé : la maladie d Alzheimer. 2 nd ed; Voyer, P. Soins infirmiers aux ainés en perte d autonomie : Une approche adaptée au CHSLD Show empathy (e.g., hold the patient s hand) Distract the patient Suggest a physical activity/task to help patient feel useful Chart what happened Ask yourself why the behaviour manifested, and be ready to play detective in order to figure it out Put a program in place to prevent future crises Treat the patient like a partner in this program (plan for daily interaction and establish daily rituals) Give the patient time to adjust to changes in the routine Adopt a proactive approach Phaneuf, M. Le vieillissement perturbé : la maladie d Alzheimer. 2 nd ed; Voyer, P. Soins infirmiers aux ainés en perte d autonomie : Une approche adaptée au CHSLD Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 12 of 20
13 What Techniques Don t Work? Taking a reactive (vs. proactive) approach Dominating the patient Reprimanding the patient for his/her behaviour Restraining the patient (except in extreme cases) Using medication as a chemical restraint Punishing the patient Touching the patient without warning him/her first and without asking permission Treating the patient like an infant As a member of staff, feeling defeated by the incident Methods: Thirty nursing home residents with frequent,severe behavioral disturbances were observed by research staff before,during, and after multiple, randomized, singleblind exposures to 15-minute audiotapes of simulated family presence (a conversation prepared by a family member about positive experiences from the past), music preferred by the resident in earlier life, and a placebo condition of a reading from a horticultural text. Selected (usually multiple) physical and verbal behaviors were counted as present or absent at regular intervals. All three treatment conditions were compared with usual care. Phaneuf, M. Le vieillissement perturbé : la maladie d Alzheimer. 2 nd ed; Voyer, P. Soins infirmiers aux ainés en perte d autonomie : Une approche adaptée au CHSLD Pharmacological Options for the Treatment of BPSD Benzodiazepines should be used only for short periods as p.r.n. agents. ChEIs & and memantine A trial of a cholinesterase inhibitor and/or memantine can be considered Antidepressants From the Consensus Guidelines: Anxiolytics Before initiating therapy with other forms of pharmacotherapy BPSD for BPSD, clinicians should consider use of the disease-specific treatments. Adapted from the Canadian Consensus Conference on Diagnosis and Treatment of Dementia SSRIs can be used for the treatment of severe depression. Trazodone: Insufficient evidence to recommend for or against the use. Atypical antipsychotics Risperidone and olanzapine can be used for severe agitation, aggression and psychosis. The potential benefit of all antipsychotics must be weighed against the potential risks such as cerebrovascular adverse events and mortality. Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 13 of 20
14 Meta-Analysis of All ChEI Trials with Behavioural Data (to 2001) ChEIs in the Canadian Guidelines Litt search of MEDLINE ( ), PubMed, Cochrane Register, etc. Searched for well-designed trials in mild-tomoderate AD with 1 month use of ChEI Found 16 such trials with neuropsychiatric measures NPI: ChEI improved 1.72 points more than placebo (95% CI, points) ADAS-non-cog: ChEI improved 0.03 points more than placebo (95% CI, points) Modest benefit on neuropsychiatric outcomes There is evidence [from trials of cognition/function/adl] of benefit on neuropsychiatric symptoms... and from one trial designed specifically with behaviour as the primary outcome measure Treatment with ChEIs might improve apathy, depression, anxiety, and psychosis Trinh NH, et al. JAMA 2003;289: Hermann N, et al. Alzheimer Dement 2007;3: Donepezil: Improvement vs. Worsening in Behaviour when Donepezil was Maintained vs. Withdrawn Pts Continuing Donepezil had Improvement in NPI (vs. Worsening for Discontinuing) Randomized withdrawal study, mild-to-mod AD All pts received donepezil for 12 weeks, then either donepezil or placebo for 12 more weeks 134 pts with mild-to-mod AD and marked BPSD Pts who continued donepezil had better NPI scores than withdrawal group (mean change -2.9 vs points; p= 0.02) * * p<0.001 vs. baseline ** p<0.05 for between-group difference * ** ** Holmes C, et al. Neurology 2004;63(2): Adapted from Holmes C, et al. Neurology 2004;63(2): Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 14 of 20
15 Donepezil: No Benefit on NPI in Moderate-to-Severe AD Donepezil: No Benefit on Behaviour in Severe AD 24-week, placebo-controlled, randomized trial 208 nursing home pts (mean MMSE = 14.4) Nursing Home version of NPI was the primary outcome No significant difference on NPI for donepezil vs. placebo at Week 24 6-month, double-blind, parallel-group, placebo-controlled study 248 nursing home pts (MMSE of 1-10) NPI was a secondary outcome No significant benefit on behaviour Tariot PN, et al. J Am Geriatr Soc 2001;49(12): Winblad B, et al. Lancet 2006;367(9516): Rivastigmine: Effect on Behaviour Comparable to Donepezil in Moderate AD Rivastigmine: No Improvement in Agitation in Severe AD 2-year, randomized, head-to-head comparison of donepezil and rivastigmine 994 nursing home pts (mean MMSE 15.1) NPI was a secondary measure Similar worsening of behaviour seen for both treatment groups Authors note that decline was significantly smaller than would be expected from untreated patients 26-week, double-blind, placebo-controlled, RCT of rivastigmine vs. quetiapine 93 nursing home pts with significant agitation Primary outcomes included agitation Compared with placebo, neither group showed significant differences in improvement on the agitation inventory either at six weeks or 26 weeks Bullock R, et al. Curr Med Res Opin 2005;21(8): Ballard C, et al. BMJ 2005;330(7496):874. Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 15 of 20
16 Rivastigmine: Improvement in Behaviour in Mod to Sev AD Impact of Memantine on Use of Psychotropics in Real World Setting Analysis of data from a 26-week prospective open-label study + 26-week extension 173 nursing home pts with mod-to-sev AD taking rivastigmine 1.5 to 6 mg bid Significant improvements in 10 of the 12 behavioural domains of the Nursing Home version of the NPI (including delusions, hallucinations, anxiety, euphoria) 40% of pts taking antipsychotics reduced dose or discontinued Edwards K, et al. Clin Drug Investig 2005;25(8): Study of all patients in French national health insurance plan taking memantine (n=4,600) Evaluated use of psychotropics before and after a specific event: the first purchase of memantine Database covered, on average, 11.7 months before and 11.2 months after first purchase of memantine Before memantine: Psychotropic use increasing After memantine: Psychotropic use stopped increasing Vidal J-S, et al. Neuroepidemiology 2008;31: Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 16 of 20
17 Pooled-Data Analysis of all 6 Studies of Memantine and Behaviour Memantine Patients Showed an Improvement in Agitation/Aggression Memantine was found to: 1-3 Improve NPI total score Improve some individual items (particularly agitation/aggression) Effect on agitation was seen in patients: With the symptom at baseline (i.e., improvement) Without the symptom at baseline (i.e., delayed emergence) 1. Winblad B, et al. Dement Geriatr Cogn Disord 2007;24: Maidment ID, et al. Annals Pharmacother 2008;42(1): Gauthier S, et al. Int J Geriatr Psychiatry 2008;23(5): Percentage of patients showing improvement at week 24/28 (LOCF) * Delusions Hallucinations Agitation/aggression *p<0.05 * Depression/dysphoria Anxiety Elation/euphoria Apathy/indifference Adapted from Gauthier S et al. Int J Geriatr Psychiatry 2008;23(5): Memantine * Disinhibition Irritability/lability Aberrant motor behaviour Placebo Night-time behaviour Appetite/eating change Memantine Prevented the Emergence of Agitation/Aggression Can Memantine Delay Time to Nursing Home Placement? Percentage of patients remaining asymptomatic at week 24/28 (LOCF) Delusions *p=0.05; **p<0.01; ***p=0.001 Hallucinations *** Agitation/aggression Depression/dysphoria Anxiety Elation/euphoria Apathy/indifference Adapted from Gauthier S et al. Int J Geriatr Psychiatry 2008;23(5): Memantine Disinhibition ** Irritability/lability Aberrant motor behaviour Placebo * Night-time behaviour Appetite/eating change Retrospective analysis of data from AD patients at the Alzheimer s Disease Research Center in Pittsburgh Sub-cohort (created to account for differences related to the year of entry into the study) involved 429 pts enrolled on or after July 29, 1997, with at least one year of follow-up 140 pts used ChEIs + memantine 289 pts used ChEIs only Lopez OL et al. J Neurol Neurosurg Psychiatry. Published online 9 Feb Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 17 of 20
18 Patients Taking Memantine + ChEI Were Seven Times Less Likely to Enter Nursing Home vs. Patients Taking ChEI Alone Proportion of Patients Taking Memantine + ChEI vs. ChEI Alone Entering Nursing Home or Using Sedatives, Anxiolytics, or Hypnotics Survival Distribution Function Relative Hazard 0.13 (95% CI: ) p<0.001* Follow-up time, in years * Derived from fully adjusted Cox model Lopez OL et al. J Neurol Neurosurg Psychiatry. Published online 9 Feb Memantine + ChEIs 2. ChEIs alone Portion of patients entering nursing home Portion of patients taking sedatives, anxiolytics, and hypnotics ChEI monotherapy Lopez OL et al. J Neurol Neurosurg Psychiatry. Published online 9 Feb ChEI + memantine p-value 18% 5% < % 8% Impact of Memantine on Use of Psychotropics in Real World Setting Database covered, on average, 11.7 months before and 11.2 months after first purchase of memantine Researchers evaluated trend line effects Results: Before memantine: Psychotropic use increasing After memantine: Psychotropic use stopped increasing Trend seen for all psychotropics and every subgroup Vidal J-S et al. Neuroepidemiology 2008;31: Similar Decline Seen with all Psychotropics Treatment ß Coefficients (CI) Pre Memantine Post Memantine Any Psychotropic Antidepressants Neuroleptics Anxiolytics Hypnotics (0.025 to 0.036) (0.015 to 0.028) (0.046 to 0.068) (0.017 to 0.031) ( to 0.016) ( to 0.002) ( to 0.005) ( to 0.018) ( to 0.010) ( to 0.007) p value < < < < Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 18 of 20
19 Significant Difference in Neuroleptics Use after Starting Memantine Why Did Psychotropics Increase Sharply at Time of Memantine Purchase? Use Increasing ß=0.057 (CI to 0.068) (p<0.0001) Use decreasing slightly ß= (CI ) May signify abrupt deterioration, which led to simultaneous Rx of more psychotropic drugs and memantine Could be explained (at least partly) by simultaneous purchase of all drugs prescribed in addition to memantine (because interrupting event was first purchase of memantine) Vidal J-S et al. Neuroepidemiology 2008;31: Vidal J-S et al. Neuroepidemiology 2008;31: Continuing with Henry s Case Could Henry s Current Situation Have Been Avoided? Travel Back in Time 6 Weeks Ago: On admission, Henry s grown children warned that he was fussy about personal care, but that their mother had a knack for calming him down He has significant deafness, which makes communication difficult Cont d... Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 19 of 20
20 Could Henry s Current Situation Have Been Avoided? Could Henry s Current Situation Have Been Avoided? Over the Past 6 Weeks: Henry has wandered the unit aimlessly, often irritable Becomes agitated and resistive during personal care Has been sad and occasionally cries, asking where is my wife? Over the Past 2 weeks: Henry has experienced significant changes in his sleep He has become even more agitated and irritable He has had a harder time hearing what the staff are saying Also, for the first time, Henry has been off balance (was he taking all these meds at home?) Cont d... Strategies for Treating Henry Key Take-Home Messages Review his medications and consider changes Stop any that may be unnecessary (e.g., naprosyn, diphenhydramine, codeine and ranitidine) Add potentially helpful meds (e.g. memantine) Look at environmental triggers and interactions that lead to agitation R/O delirium Seek input to determine from family and nursing staff Behaviour is a complex issue A bio-psycho-social approach is essential Environmental and approach strategies may be most effective BUT are difficult to implement Antipsychotics are complex drugs to utilize Memantine is an alternative approach Geriatric Grand Rounds, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada (April 14, 2009) Page 20 of 20
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationAcross the Spectrum of Dementia. Keys to Understanding Behaviours & Anticipating Needs
Across the Spectrum of Dementia Keys to Understanding Behaviours & Anticipating Needs Outline Review current predictions for dementia prevalence, & the implications for future needs Discuss retrogenesis
More informationLTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationBehaviour Units: Understanding what they can offer Older Patients with Dementia
Behaviour Units: Understanding what they can offer Older Patients with Dementia David K. Conn Baycrest Centre and University of Toronto 2013 Mount Sinai Geriatrics institute Outline Alice s journey continues
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationBehavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad
Behavioral Management in Dementia a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad Game Plan 1. Definition 2. Epidemiology 3. Assessment: IT S OVER 4. Nonpharmacologic Strategies: 4 S 5. Nonpharmacologic:
More informationHow I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C)
How I Treat Aggression in Outpatients With Dementia C. Omelan MD, FRCP(C) Conflict of Interest I have no potential conflicts of interest to declare Overview Outline the prevalence of aggression Review
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationNeuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
More informationManaging agitation in dementia using non-pharmacological therapies
Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationRecognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationRisks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
More informationGuidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationDelirium. Approach. Symptom Update Masterclass:
Symptom Update Masterclass: Delirium Jason Boland Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine Wolfson Centre for Palliative Care Research Hull York Medical School University
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationParkinsonian Disorders with Dementia
Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationThe Agitated. Older Patient: old. What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003
Focus on CME at Queen s University Focus on CME at Queen s University The Agitated The Older Patient: What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003 Both
More informationNeuropsychiatric Inventory Nursing Home Version (NPI-NH)
This is a Sample version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) The full version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) comes without sample watermark..
More informationOctober 28, Geriatrics Update Course. Lesley Wiesenfeld, MD, MHCM, FRCPC. Managing BPSD. Geriatric Psychiatrist, Mount Sinai Hospital
October 28, 2016 Geriatrics Update Course Managing BPSD Lesley Wiesenfeld, MD, MHCM, FRCPC Geriatric Psychiatrist, Mount Sinai Hospital Disclosures ~No Pharmaceutical or Industry Support ~ No Health Without
More informationMedications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center
Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points
More informationAddressing Difficult Behaviors in Dementia
Addressing Difficult Behaviors in Dementia GEORGE SCHOEPHOERSTER, MD GERIATRICIAN GENEVIVE/CENTRACARE CLINIC Objectives By the end of the session, you will be able to: 1) Explain the role of pain management
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationThe Neuropsychiatric Inventory Questionnaire: Background and Administration
The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire (NPI-Q) was developed and crossvalidated with the standard NPI to provide a brief
More informationOutcomes in GEM models of geriatric care: How do we measure success? Disclosure. Objectives. Geriatric Grand Rounds
Geriatric Grand Rounds Tuesday, October 7, 2008 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital Outcomes in GEM models of geriatric care: How do we measure success? In keeping with
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationTHE BEHAVIOURAL VITAL SIGNS (BVS) TOOL
DID YOU KNOW THE BEHAVIOURAL VITAL SIGNS (BVS) TOOL. Did you know that it is essential to know the target cluster(s)/symptom(s) one is treating to guide and monitor non-pharmacological approaches and pharmacological
More informationFrom Neurodevelopment to Neurodegeneration: Behavioral Issues
From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to
More informationBehavioral Interventions
Behavioral Interventions Linda K. Shumaker, R.N.-BC, MA Pennsylvania Behavioral Health and Aging Coalition Behavioral Management is the key in taking care of anyone with a Dementia! Mental Health Issues
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationManaging Behavioral Issues
2:45 3:45pm Caring for the Older Patient Handling Behavioral Issues Presenter Disclosure Information The following relationships exist related to this presentation: Samir Sabbag, MD, has no financial relationships
More informationOlder People Mental Health - new directorate/new plans. Dr Adrian Treloar Clinical director
Older People Mental Health - new directorate/new plans Dr Adrian Treloar Clinical director Dementia 700,000 people in the UK currently have dementia; this number is set to double by 2038 1/3 of people
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationHow Aging and Dementia Effect Resident Behaviors
How Aging and Dementia Effect Resident Behaviors November 3, 2011 1:00 2:00 PM EST Webinar Presented by: Alfred W. Norwood, BS, MBA Education Arm of the Carmelite Sisters for the Aged and Infirm Webinar
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationDementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
More informationAssessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationResponsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease
ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationLewy Body Disease. Dementia Education for the First Responder July 27, 2017
Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationMental Health Issues in Nursing Homes. I m glad you asked.
Mental Health Issues in Nursing Homes I m glad you asked. I m glad you asked Susan Wehry, M.D. Associate Professor of Psychiatry, College of Medicine, University of Vermont Consultant, State of Vermont
More informationOBJECTIVES. Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia
Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia Amy J. Osborn, NHA, PMP Executive Director, Health Services Advisory Group (HSAG) Rick Foley, PharmD,
More informationCaring for a Patient or Family Member with Alzheimer s Disease or Related Dementia
Caring for a Patient or Family Member with Alzheimer s Disease or Related Dementia Tiffany D. Long, MS4 UNC School of Medicine MD Candidate Class of 2018 Disclaimers A portion of this project is/was supported
More informationAn Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E.
An Evaluation of a Training Program in Restraint-Free Care for Individuals with Dementia Christina Garrison-Diehn, Clair Rummel, & Jane E. Fisher Background Disease. (Xu, Kochanek & Tejada-Vera, 2009)
More informationBehavior Problems: in Long Term Care and Assisted Living
Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module I Dr. David A. Smith, M.D., FAAFP, CMD mmlearn.org is a program of Morningside Ministries Cell Phones and Pagers
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationDelirium. Delirium. Delirium Etiology and Pathophysiology. Fall 2018
Three most common cognitive problems in adults 1. (acute confusion) 2. Dementia 3. Depression These problems often occur together Can you think of common stimuli for each? 1 1 State of temporary but acute
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationPalliative Care Consult Service
Creating Program Elements to Improve the Care of the Dementia Patient in Palliative & Hospice Settings Carla Jolley MN, ARNP, ANP-BC, AOCN, ACHPN Palliative Care APN/Program Coordinator WhidbeyHealth Palliative
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationPharmacologic Management of Mood and Behavioral Changes in
Pharmacologic Management of Mood and Behavioral Changes in Dementia James E. Galvin, MD, MPH Professor of Neurology and Psychiatry New York University Langone Medical Center CADASIL MRI scan showing leukoencephalopathyon
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationDr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital. November /20/ Safety: Falls/Cooking/Unsafe Behaviour. 2.
How To Decide if an Elderly Person Can Stay at Home: The Interval of Need Concept Dr. W. Dalziel Professor, Geriatric Medicine Ottawa Hospital November 2013 3 Factors 1. Safety: Falls/Cooking/Unsafe Behaviour
More informationAn Approach to Dementia-related Behaviours at the End of Life. Elisabeth Drance MD FRCP(C) Ger. Psych Clinical Associate Professor Psychiatry UBC
An Approach to Dementia-related Behaviours at the End of Life Elisabeth Drance MD FRCP(C) Ger. Psych Clinical Associate Professor Psychiatry UBC Objectives List the common behaviours occurring in late
More informationAntipsychotics in Dementia
Antipsychotics in Dementia What s all the fuss? Judy MacDonald RPh BSc Pharm Dr. Ashok Krishnamoorthy MD MRCPsych FRCPC ABAM MS (Neuro Psych) Learning Objectives Recognize common behavioural & psychological
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA: A PRACTICAL APPROACH. Andrea Moser Sid Feldman
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA: A PRACTICAL APPROACH Andrea Moser Sid Feldman Disclosure Dr. Sid Feldman No conflicts of interest to report Disclosure Dr. Andrea Moser No conflicts
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationCoordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis
Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis Jeff Gelblum, MD Senior Attending Neurologist Mt. Sinai Medical Center Miami,
More informationMedication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015
Medication Management Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015 1 Medication Management Objectives: 1. Principles of psycho-pharmacology
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Prevalence and Risk Factors of Delirium in Older Patients Admitted to a Community Based Acute Care Hospital Tuesday, October 27, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationUpdate in Geriatrics: Choosing Wisely Primum Non Nocere
Joseph G. Ouslander, M.D. Professor of Clinical Biomedical Science Senior Associate Dean for Geriatric Programs Chair, Department of Integrated Medical Science Charles E. Schmidt College of Medicine Professor
More informationDelirium. Geriatric Giants Lecture Series Divisions of Geriatric Medicine and Care of the Elderly University of Alberta
Delirium Geriatric Giants Lecture Series Divisions of Geriatric Medicine and Care of the Elderly University of Alberta Overview A. Delirium - the nature of the beast B. Significance of delirium C. An approach
More informationNeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
More informationWorkshop cases answers
Workshop cases answers BPSD Workshop: case histories Case 1: Mrs DM Scenario This is an 83 year old lady diagnosed with multi infarct dementia in 2008. Lives with husband and the couple are supported by
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationAntipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses
658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationQUESTIONNAIRE: Finland
QUESTIONNAIRE: Finland To put the assessment and management of behavioural disorders into a broader context of social and health policy and services in Finland, some background information is presented.
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationPharmacologyonline 1: (2009) ewsletter Rosanna Erra. Atypical Antipsychotic Drugs for the Treatment of BPSD. in Subjects with Dementia
Atypical Antipsychotic Drugs for the Treatment of BPSD in Subjects with Dementia Rosanna Erra School of Pharmacy, University of Salerno, Italy ros.erra@libero.it Summary Behavioural and psychological disorders
More information